Therapeutic spectrum in the treatment of myelodysplastic syndromes
Authors:
- Wolf-K HofmannWHWolf-K Hofmann
- Claudia BaldusCBClaudia Baldus
- Lutz UharekLULutz Uharek
- Eckhard ThielETEckhard Thiel
- 1 December 2004
- journal article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 5 (12) , 2451-2458
Abstract
During the last 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndromes (MDS). It is a clonal disorder, characterised by ineffective haematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukaemias. Risk-adapted treatment strategies were established, due to the high median age (60 - 75 years) of the MDS patients and the individual history of the disease (i.e. number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the 'typical' MDS patient, who is > 60 years of age. Therapy with erythropoietin and granulocyte colony-stimulating factor has improved the quality of life of selected patients. The development of target-specific therapies, including antibodies and small molecules directed against specific molecular alterations in MDS, with minimal adverse effects, is the hope for the future. Furthermore, the innovative use of immunomodulatory agents and the optimising of cytotoxic treatment should continue to help in the treatment of MDS.Keywords
This publication has 40 references indexed in Scilit:
- Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expressionLeukemia Research, 2004
- The WHO classification of MDS does make a differenceBlood, 2004
- A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromesLeukemia, 2004
- Opportunities for Trisenox® (arsenic trioxide) in the treatment of myelodysplastic syndromesLeukemia, 2003
- The World Health Organization (WHO) classification of the myeloid neoplasmsBlood, 2002
- Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factorsLeukemia, 2002
- Good response to cyclosporine therapy in patients with myelodysplastic syndrromes having the HLA-DRB1*1501 alleleLeukemia, 2000
- Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic TrioxideNew England Journal of Medicine, 1998
- Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte‐mediated inhibition of CFU‐GM and alterations in T‐cell receptor Vβ profilesBritish Journal of Haematology, 1998
- Cellular differentiation, cytidine analogs and DNA methylationCell, 1980